{"ticker": {"uuid": "bb53a80f-a50d-4d92-87a2-0a8a76332321", "symbol": "GANX", "name": "Gain Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Gain Therapeutics (GANX) Q1 2026 earnings summary", "summary": "Gain Therapeutics (GANX) reported a Q1 2026 net loss of $5.6 million, or $0.13 per share, with increased R&D and G&A expenses due primarily to the GT-02287 program for Parkinson's disease. The company anticipates IND clearance for GT-02287 in Q2 2026 and Phase 2 trial initiation ", "url": "https://quartr.com/events/gain-therapeutics-inc-ganx-q1-2026_Fk8Ybe2C", "source_name": "Quartr", "published_at": "2026-07-13T05:10:14", "published_display": "13 Jul 2026 05:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) Q4 2025 earnings summary", "summary": "Gain Therapeutics (GANX) reported its Q4 2025 earnings, highlighting advancements in its Parkinson's disease candidate, GT-02287, which showed promising Phase 1b data and disease-modifying potential. The company saw a decrease in both R&D and G&A expenses, leading to a slightly r", "url": "https://quartr.com/events/gain-therapeutics-inc-ganx-q4-2025_Fk8YwT2f", "source_name": "Quartr", "published_at": "2026-07-12T16:40:59", "published_display": "12 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) The 38th Annual Roth Conference Summary", "summary": "This article summarizes Gain Therapeutics' presentation at the 38th Annual Roth Conference, focusing on their therapeutic approach for Parkinson's disease. The company uses its Magellan platform to develop GT-02287, a drug designed to stabilize the GCase protein and modify the di", "url": "https://quartr.com/events/gain-therapeutics-inc-ganx-the-38th-annual-roth-conference_Fk8Yb9RS", "source_name": "Quartr", "published_at": "2026-07-12T11:39:50", "published_display": "12 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With new FDA green light for developer, Parkinson\u2019s clinical trial to launch soon", "summary": "The FDA has approved Gain Therapeutics to begin a clinical trial for its oral Parkinson's therapy, GT-02287. This therapy aims to prevent toxic protein clumps from forming in the brain by restoring the activity of the GCase enzyme. Previous studies showed GT-02287 to be safe and ", "url": "https://parkinsonsnewstoday.com/news/fda-gives-green-light-clinical-trial-testing-oral-parkinsons-therapy/", "source_name": "Parkinson's News Today", "published_at": "2026-07-07T04:09:59", "published_display": "07 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Gain Therapeutics, Inc. \u2013 NASDAQ:GANX", "summary": "The article provides a financial metric for Gain Therapeutics, Inc. (NASDAQ: GANX), specifically its enterprise value to EBIT (Earnings Before Interest and Taxes) forward. It appears to be a stub or partial financial data point from TradingView, indicating a period value, and cha", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T15:10:00", "published_display": "04 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Gain Therapeutics, Inc. \u2013 NASDAQ:GANX", "summary": "This article provides the enterprise value to revenue forward for Gain Therapeutics, Inc. (NASDAQ: GANX). The financial data is available on TradingView, which also provides additional market and company information.", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T07:40:20", "published_display": "04 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7", "summary": "Maxim Group has reiterated its Buy rating for Gain Therapeutics (GANX.US) and maintained its price target at $7. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72414952/maxim-group-maintains-gain-therapeutics-ganxus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-03T14:10:00", "published_display": "03 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson\u2019s Disease", "summary": "Gain Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for GT-02287, allowing it to advance into Phase 2 clinical development for Parkinson\u2019s disease in the U.S. This decision follows positive Phase 1 results demonstrating favorable sa", "url": "https://biobuzz.io/news/gain-therapeutics-receives-fda-clearance-of-ind-to-advance-gt-02287-into-phase-2-clinical-development-for-parkinsons-disease/", "source_name": "BioBuzz", "published_at": "2026-07-02T03:39:57", "published_display": "02 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval", "summary": "H.C. Wainwright has reiterated a Buy rating and an $8.00 price target for Gain Therapeutics (NASDAQ:GANX) after the FDA authorized the company's Investigational New Drug application for GT-02287. This FDA decision allows Gain Therapeutics to initiate Phase 2 clinical assessment i", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-gain-therapeutics-stock-rating-on-fda-approval-93CH-4770239", "source_name": "Investing.com", "published_at": "2026-07-02T02:11:28", "published_display": "02 Jul 2026 02:11", "sentiment": "positive", "sentiment_pct": 91, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Is Maintained at Buy by BTIG", "summary": "BTIG has reiterated its Buy rating for Gain Therapeutics (NASDAQ:GANX). The article does not provide a specific price target or further details on the analyst's rationale.", "url": "https://www.moomoo.com/news/post/72283281/gain-therapeutics-is-maintained-at-buy-by-btig", "source_name": "Moomoo", "published_at": "2026-07-01T14:42:48", "published_display": "01 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GANX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00", "summary": "HC Wainwright & Co. has reiterated its 'Buy' rating for Gain Therapeutics (GANX), maintaining a price target of $8.00, significantly higher than its current trading price of $2.03. While the company's GF Score of 32/100 indicates potential weaknesses in profitability and growth, ", "url": "https://www.gurufocus.com/news/8940761/ganx-reiterated-by-hc-wainwright-co-price-target-maintained-at-800", "source_name": "GuruFocus", "published_at": "2026-07-01T13:39:59", "published_display": "01 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNRXlXRGVfSXY3QlA5YXliWFhTdC00eE5tRFdoeXlmSFpYa3czbkZ0RHhSN0hLdmVvaWtqTmJOdVZ6TzZ3RWc1blpkUE41QWotdUk5VWJQdWp1dVdsSWd6Z0dCZUptZzl3Q2NELWJWNnpZNUVQa080WUJFRUNWUFZoYjJjQ2d3R1VsOTBKdmRUTnFEM3RuMTlnQVBST20wa0htUWc3Snh2UFgwU3RDNzJJaw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines", "summary": "This article highlights several stocks for investors to watch, including AeroVironment (AVAV), Concentrix (CNXC), Gain Therapeutics (GANX), and Praxis Precision Medicines (PRAX). Each company's stock is experiencing specific market movements or has upcoming events that could impa", "url": "https://www.moomoo.com/news/post/72214140/stocks-to-watch-aerovironment-concentrix-gain-therapeutics-praxis-precision-medicines", "source_name": "Moomoo", "published_at": "2026-06-30T13:11:43", "published_display": "30 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 Into Phase 2 Development for Parkinson's Disease", "summary": "Gain Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for GT-02287, allowing the company to proceed with Phase 2 clinical trials for Parkinson's disease. GT-02287 is a brain-penetrant allosteric activator of GCase, designed to address", "url": "https://www.moomoo.com/news/post/72209818/gain-therapeutics-receives-fda-clearance-of-ind-to-advance-gt?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-30T12:39:29", "published_display": "30 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Gain Therapeutics, Inc. \u2013 NASDAQ:GANX", "summary": "This article provides information on the number of shareholders for Gain Therapeutics, Inc. (NASDAQ: GANX). It is a financial data point from TradingView, which aggregates market data from various sources. The article itself does not provide the specific number of shareholders, b", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-30T12:39:29", "published_display": "30 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Gain Therapeutics, Inc. \u2013 NASDAQ:GANX", "summary": "The article focuses on the \"Price to sales forward\" metric for Gain Therapeutics, Inc. (NASDAQ: GANX). It presents financial data related to this metric, indicating its value, change, and percentage change over a specified period. The information is provided by TradingView, with ", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T08:10:02", "published_display": "30 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics stock surges on FDA clearance for Parkinson\u2019s drug By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNelR1ZmJHNGQ3QjhQWnJjR3NlclU3M3Q5c2lqbVIxRmNLbENGdWdmTlRLZ0JBcXpmOGxDNkt4VHgyMXZrd3RvREpkZ0JCNVRGbXBRaXBaTUdOeUdCcU1LcUUtdlhieUIwUGpOM2xQQmdubnFhcWUtaWoxVVgxS09LRzFpbGctZTVxYnhUXzY1R3JsWk5UWnRBTG80V1IxSW94ajM1QXRWRnFoWjYtUU5UYUUtTWY2eTBubnJnZlh5QkotdFZONnZn?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-29T20:43:03+00:00", "published_display": "29 Jun 2026 20:43", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/gain-therapeutics-gets-us-fda-203617517.html", "source_name": "MT Newswires", "published_at": "2026-06-29T20:36:17+00:00", "published_display": "29 Jun 2026 20:36", "sentiment": "positive", "sentiment_pct": 58, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics stock surges on FDA clearance for Parkinson\u2019s drug", "summary": "Gain Therapeutics Inc. (NASDAQ:GANX) saw its shares rise significantly after the FDA cleared its Investigational New Drug application for GT-02287, a Parkinson\u2019s disease treatment. This clearance allows the company to initiate a Phase 2 clinical trial in the U.S. in Q3 2026, foll", "url": "https://m.in.investing.com/news/stock-market-news/gain-therapeutics-stock-surges-on-fda-clearance-for-parkinsons-drug-93CH-5475234?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-29T20:41:44", "published_display": "29 Jun 2026 20:41", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) wins FDA IND clearance to start GT-02287 Phase 2 Parkinson\u2019s trial", "summary": "Gain Therapeutics (GANX) announced that the FDA has authorized its Investigational New Drug (IND) application for GT-02287. This clearance allows the company to proceed with Phase 2 clinical trials in the United States for Parkinson's disease, with or without a GBA1 mutation. The", "url": "https://www.stocktitan.net/sec-filings/GANX/8-k-gain-therapeutics-inc-reports-material-event-efa118a2710f.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:41:44", "published_display": "29 Jun 2026 20:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears Gain Therapeutics drug GT-02287 for Phase 2 Parkinson\u2019s trial", "summary": "Gain Therapeutics (NASDAQ: GANX) has received FDA clearance for its Investigational New Drug (IND) application for GT-02287, allowing it to proceed with Phase 2 clinical development for Parkinson's disease in the U.S. This decision follows positive Phase 1 results that showed fav", "url": "https://www.stocktitan.net/news/GANX/gain-therapeutics-receives-fda-clearance-of-ind-to-advance-gt-02287-lw5rfm3izgpz.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:44", "published_display": "29 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 93, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Gain Therapeutics, Inc. \u2013 NASDAQ:GANX", "summary": "This article provides information about the \"Price to earnings forward\" for Gain Therapeutics, Inc. (NASDAQ: GANX). It appears to be a financial data point available on TradingView, indicating a specific financial metric for the company. The content itself seems to be a financial", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T15:41:44", "published_display": "29 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Clinical-Stage Biotech Stocks Worth Watching In Parkinson's Research", "summary": "This article highlights three clinical-stage biotech companies, Gain Therapeutics (GANX), MeiraGTx Holdings (MGTX), and Alto Neuroscience (ANRO), that are actively involved in Parkinson's research. It discusses their current clinical progress, market capitalization, revenue, and ", "url": "https://www.sahmcapital.com/news/content/3-clinical-stage-biotech-stocks-worth-watching-in-parkinsons-research-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-25T23:41:44", "published_display": "25 Jun 2026 23:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics, Inc. Actuals & Estimates (NASDAQ:GANX)", "summary": "This article provides an overview of Gain Therapeutics, Inc. (NASDAQ:GANX) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue, and addresses common investor question", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:26", "published_display": "25 Jun 2026 22:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) shareholders back board slate and Ernst & Young AG at 2026 meeting", "summary": "Gain Therapeutics, Inc. held its annual stockholder meeting on June 24, 2026, where shareholders elected seven directors to one-year terms and ratified Ernst & Young AG as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The director", "url": "https://www.stocktitan.net/sec-filings/GANX/8-k-gain-therapeutics-inc-reports-material-event-325237341616.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:59:39", "published_display": "25 Jun 2026 20:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GANX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Gain Therapeutics, Inc. (GANX) stock, including analyst price targets, historical performance, and essential financial data. It highlights that five analysts have offered a 1-year price forecast, with a maximum estimate of $8.00 and a minimum ", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:09:57", "published_display": "25 Jun 2026 17:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Inc (GANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Gain Therapeutics Inc (GANX), detailing its price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock currently has a price momentum score of 7.01 and is trading betwee", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ganx/technical", "source_name": "TradingKey", "published_at": "2026-06-22T09:10:59", "published_display": "22 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Gain Therapeutics Inc (GANX), highlighting its current earnings forecast score of 8.80 within the Biotechnology & Medical Research industry. It details analyst ratings, with a strong buy consensus and a target price of $7.00, along w", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ganx/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T20:09:56", "published_display": "19 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Inc (GANX) Institutional Confidence", "summary": "Gain Therapeutics Inc (GANX) has an institutional shareholding score of 3.00, ranking 193rd out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 20.25%, marking a 58.16% increase quarter-over-quarter. Bill Nygren | OAKMX", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ganx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T03:10:58", "published_display": "19 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Inc (GANX) Valuation: PE, PB & Fair Value Analysis", "summary": "Gain Therapeutics Inc (GANX) has a current valuation score of 6.04, placing it in the lower quartile of the Biotechnology & Medical Research industry. The company's P/E ratio stands at -3.21, significantly below its recent high but above its recent low. Key valuation metrics like", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ganx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T03:10:58", "published_display": "19 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gain-therapeutics-present-h-c-110000181.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T11:00:00+00:00", "published_display": "10 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics expands \u2018compelling\u2019 evidence base for Parkinson\u2019s candidate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gain-therapeutics-presents-positive-interim-120000888.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T12:00:00+00:00", "published_display": "26 May 2026 12:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gain-therapeutics-reports-financial-results-110000886.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T11:00:00+00:00", "published_display": "11 May 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNMFFpOWNoOEhDSXBMaWpoLXBmQkVkS1pZZ0JRSF9Ibk8xRGNpeVlzc2h3MkRiVnhwa3pPOXg3d2UwNE9FbVpGblZRVnAxMkttN3FmWVU4VnpROXlWSEpKeWw5aVVqQ3lyNmtpaUtwZDNROGdwWDY3WFNDOWFmQVQ5emF2VUZ4aFlaYngzVE4tdmhkNUY1Y2VIQVhTUnpDMjZGakwyMVh3?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "GANX | Gain Therapeutics, Inc. Common Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBWS3RXREJELUd6YXJaYXNPbzVJQWR0UWhJSXJXUTNUUUxkT1Z1cUMyYTZnWVZ0YWtWUTgzbGw0NEtjMnpfTlZJNDJNa1k5NFJFQXNKbGdrZW8zb0hB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-17T06:43:50+00:00", "published_display": "17 Apr 2026 06:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotech firm Gain Therapeutics lines up three events in San Francisco", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaXR1ZW04TVZoc3JOdkNHdEVwOUswaGx3Ti1vZXpZTHI3Sk1aX0RQTjdGWjRrY2EzalVsZU1taTkzQjRud3RIRnhWZ09taWNQbnNlc2NJbUEwM21ocDlTUEVXVEpQZkZWeG9jREJ0VDJWYUxYR0RNRy1BTmlJZ0MxTldYcm9JTnFWaWQ3ZXkyb0NqVGhmSzg1NzF0RjhPNlgyZnRSbkhkTjBtTEhDakdpZk5tdENKaXJn?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdFlUSGl6TXE1eGNVUThXNTFITFlxb0hFRnprc3Rmam83TGVpRTZyTUJMNmVBODJzb3BrRjd1S3BORG05VjJuVzlJSnlmZEdNclFVeGVJZHRYenZTLVpncDBKNENSUXVWNDNKLXdQLXc1cm1Cc2ZUTkJXOVp1enlpTlQ4QWNEUjlV?oc=5", "source_name": "Market source", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Sees Stock Surge Amid Positive Clinical Results and Ambitious Price Target Increase", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9UX2p6YmtINklMOGV4ejIzU2txemZldWdaSElJRkR2anQ3WGctaXdlZkJkbnpOZTlGWTlYVXVuWkpTZERqUU5GTDJxMGNmajhVU2UtaDV0bUN2ejg0UFN6LWcxaVBVZ0lFWHFTRWc3M2VBQUk1WkM3dUdmdkI?oc=5", "source_name": "StocksToTrade", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOMF9nc1llWDZqQ1U0T0N4ZEU4TnozWGp1MnJMMnhFTWhyd2FJd0tjQlBTaXFrSWE5YU5DQkx2bFM1VllZRzZQbXowWFdtMkZtZGpvR2pMcjFOT1g3WnRScFhRRVNQZzQxb3QyaUZGcWhZbnNmeGkyVjRvMlJiemdjQjFlRQ?oc=5", "source_name": "Market source", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQR1ptbTZqU0NuMTR6WnhGaV9mWWFlMWFhLU5uZ3FyQlJ4ci0xRzRTT1V1ZzI2VHFjQTBzWHhwME10cVJKb1VZSjhfMFBxcFdkQWNYNDYyYWVJWFFYaWRaYlg2MUJJZHdwVXhnRGtLSXNackNZWGRvVGdzYzh3X3ZGZ2pPSmNmLWQ0d0tVN21VUEwzemRxbUVnMm1BNmhNc3Vldm5xdGRRWEZ0akFuWHA4Y2xlOXQ4WC01d1o0UXd6cmRmbEU1LWJ2OVVhRlktRnBSQ3RMaXFYUzRrUkg3X3Vsek9B?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-07T08:00:00+00:00", "published_display": "07 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAyLThUNzFudmk1aEFobks0Q1R6WTJpWE5UZ3J4N1hCVjNwVUMyTUx5dlA0WVgxZTR3ZVZmd01ucVhSWTlqRG1hQW5NMXFCa2otekJF?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:56:17+00:00", "published_display": "25 Apr 2025 01:56", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBkRWN6VVNUX2xjQjVweGZQUnotLU9UbE1YRHIyb01xV3ZvRGctUmpPeFlpNHZkQy1rVVEydHhTbG83bURocnA3TjJSR1BqQQ?oc=5", "source_name": "Stock Titan", "published_at": "2021-03-21T19:32:46+00:00", "published_display": "21 Mar 2021 19:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Gain Therapeutics (GANX) Q1 2026 earnings summary", "summary": "Gain Therapeutics (GANX) reported a Q1 2026 net loss of $5.6 million, or $0.13 per share, with increased R&D and G&A expenses due primarily to the GT-02287 program for Parkinson's disease. The company anticipates IND clearance for GT-02287 in Q2 2026 and Phase 2 trial initiation ", "url": "https://quartr.com/events/gain-therapeutics-inc-ganx-q1-2026_Fk8Ybe2C", "source_name": "Quartr", "published_at": "2026-07-13T05:10:14", "published_display": "13 Jul 2026 05:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) Q4 2025 earnings summary", "summary": "Gain Therapeutics (GANX) reported its Q4 2025 earnings, highlighting advancements in its Parkinson's disease candidate, GT-02287, which showed promising Phase 1b data and disease-modifying potential. The company saw a decrease in both R&D and G&A expenses, leading to a slightly r", "url": "https://quartr.com/events/gain-therapeutics-inc-ganx-q4-2025_Fk8YwT2f", "source_name": "Quartr", "published_at": "2026-07-12T16:40:59", "published_display": "12 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) The 38th Annual Roth Conference Summary", "summary": "This article summarizes Gain Therapeutics' presentation at the 38th Annual Roth Conference, focusing on their therapeutic approach for Parkinson's disease. The company uses its Magellan platform to develop GT-02287, a drug designed to stabilize the GCase protein and modify the di", "url": "https://quartr.com/events/gain-therapeutics-inc-ganx-the-38th-annual-roth-conference_Fk8Yb9RS", "source_name": "Quartr", "published_at": "2026-07-12T11:39:50", "published_display": "12 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With new FDA green light for developer, Parkinson\u2019s clinical trial to launch soon", "summary": "The FDA has approved Gain Therapeutics to begin a clinical trial for its oral Parkinson's therapy, GT-02287. This therapy aims to prevent toxic protein clumps from forming in the brain by restoring the activity of the GCase enzyme. Previous studies showed GT-02287 to be safe and ", "url": "https://parkinsonsnewstoday.com/news/fda-gives-green-light-clinical-trial-testing-oral-parkinsons-therapy/", "source_name": "Parkinson's News Today", "published_at": "2026-07-07T04:09:59", "published_display": "07 Jul 2026 04:09", "sentiment": "positive", "sentiment_pct": 86, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Gain Therapeutics, Inc. \u2013 NASDAQ:GANX", "summary": "The article provides a financial metric for Gain Therapeutics, Inc. (NASDAQ: GANX), specifically its enterprise value to EBIT (Earnings Before Interest and Taxes) forward. It appears to be a stub or partial financial data point from TradingView, indicating a period value, and cha", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T15:10:00", "published_display": "04 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Gain Therapeutics, Inc. \u2013 NASDAQ:GANX", "summary": "This article provides the enterprise value to revenue forward for Gain Therapeutics, Inc. (NASDAQ: GANX). The financial data is available on TradingView, which also provides additional market and company information.", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T07:40:20", "published_display": "04 Jul 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7", "summary": "Maxim Group has reiterated its Buy rating for Gain Therapeutics (GANX.US) and maintained its price target at $7. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/72414952/maxim-group-maintains-gain-therapeutics-ganxus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-07-03T14:10:00", "published_display": "03 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson\u2019s Disease", "summary": "Gain Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for GT-02287, allowing it to advance into Phase 2 clinical development for Parkinson\u2019s disease in the U.S. This decision follows positive Phase 1 results demonstrating favorable sa", "url": "https://biobuzz.io/news/gain-therapeutics-receives-fda-clearance-of-ind-to-advance-gt-02287-into-phase-2-clinical-development-for-parkinsons-disease/", "source_name": "BioBuzz", "published_at": "2026-07-02T03:39:57", "published_display": "02 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright reiterates Gain Therapeutics stock rating on FDA approval", "summary": "H.C. Wainwright has reiterated a Buy rating and an $8.00 price target for Gain Therapeutics (NASDAQ:GANX) after the FDA authorized the company's Investigational New Drug application for GT-02287. This FDA decision allows Gain Therapeutics to initiate Phase 2 clinical assessment i", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-gain-therapeutics-stock-rating-on-fda-approval-93CH-4770239", "source_name": "Investing.com", "published_at": "2026-07-02T02:11:28", "published_display": "02 Jul 2026 02:11", "sentiment": "positive", "sentiment_pct": 91, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Is Maintained at Buy by BTIG", "summary": "BTIG has reiterated its Buy rating for Gain Therapeutics (NASDAQ:GANX). The article does not provide a specific price target or further details on the analyst's rationale.", "url": "https://www.moomoo.com/news/post/72283281/gain-therapeutics-is-maintained-at-buy-by-btig", "source_name": "Moomoo", "published_at": "2026-07-01T14:42:48", "published_display": "01 Jul 2026 14:42", "sentiment": "positive", "sentiment_pct": 69, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GANX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $8.00", "summary": "HC Wainwright & Co. has reiterated its 'Buy' rating for Gain Therapeutics (GANX), maintaining a price target of $8.00, significantly higher than its current trading price of $2.03. While the company's GF Score of 32/100 indicates potential weaknesses in profitability and growth, ", "url": "https://www.gurufocus.com/news/8940761/ganx-reiterated-by-hc-wainwright-co-price-target-maintained-at-800", "source_name": "GuruFocus", "published_at": "2026-07-01T13:39:59", "published_display": "01 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNRXlXRGVfSXY3QlA5YXliWFhTdC00eE5tRFdoeXlmSFpYa3czbkZ0RHhSN0hLdmVvaWtqTmJOdVZ6TzZ3RWc1blpkUE41QWotdUk5VWJQdWp1dVdsSWd6Z0dCZUptZzl3Q2NELWJWNnpZNUVQa080WUJFRUNWUFZoYjJjQ2d3R1VsOTBKdmRUTnFEM3RuMTlnQVBST20wa0htUWc3Snh2UFgwU3RDNzJJaw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks to Watch: AeroVironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines", "summary": "This article highlights several stocks for investors to watch, including AeroVironment (AVAV), Concentrix (CNXC), Gain Therapeutics (GANX), and Praxis Precision Medicines (PRAX). Each company's stock is experiencing specific market movements or has upcoming events that could impa", "url": "https://www.moomoo.com/news/post/72214140/stocks-to-watch-aerovironment-concentrix-gain-therapeutics-praxis-precision-medicines", "source_name": "Moomoo", "published_at": "2026-06-30T13:11:43", "published_display": "30 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 Into Phase 2 Development for Parkinson's Disease", "summary": "Gain Therapeutics announced that the FDA has cleared its Investigational New Drug (IND) application for GT-02287, allowing the company to proceed with Phase 2 clinical trials for Parkinson's disease. GT-02287 is a brain-penetrant allosteric activator of GCase, designed to address", "url": "https://www.moomoo.com/news/post/72209818/gain-therapeutics-receives-fda-clearance-of-ind-to-advance-gt?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-30T12:39:29", "published_display": "30 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Gain Therapeutics, Inc. \u2013 NASDAQ:GANX", "summary": "This article provides information on the number of shareholders for Gain Therapeutics, Inc. (NASDAQ: GANX). It is a financial data point from TradingView, which aggregates market data from various sources. The article itself does not provide the specific number of shareholders, b", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-30T12:39:29", "published_display": "30 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Gain Therapeutics, Inc. \u2013 NASDAQ:GANX", "summary": "The article focuses on the \"Price to sales forward\" metric for Gain Therapeutics, Inc. (NASDAQ: GANX). It presents financial data related to this metric, indicating its value, change, and percentage change over a specified period. The information is provided by TradingView, with ", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T08:10:02", "published_display": "30 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics stock surges on FDA clearance for Parkinson\u2019s drug By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNelR1ZmJHNGQ3QjhQWnJjR3NlclU3M3Q5c2lqbVIxRmNLbENGdWdmTlRLZ0JBcXpmOGxDNkt4VHgyMXZrd3RvREpkZ0JCNVRGbXBRaXBaTUdOeUdCcU1LcUUtdlhieUIwUGpOM2xQQmdubnFhcWUtaWoxVVgxS09LRzFpbGctZTVxYnhUXzY1R3JsWk5UWnRBTG80V1IxSW94ajM1QXRWRnFoWjYtUU5UYUUtTWY2eTBubnJnZlh5QkotdFZONnZn?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-29T20:43:03+00:00", "published_display": "29 Jun 2026 20:43", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Gets US FDA Approval to Advance GT-02287 Into Phase 2 Study for Parkinson's Disease", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/gain-therapeutics-gets-us-fda-203617517.html", "source_name": "MT Newswires", "published_at": "2026-06-29T20:36:17+00:00", "published_display": "29 Jun 2026 20:36", "sentiment": "positive", "sentiment_pct": 58, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics stock surges on FDA clearance for Parkinson\u2019s drug", "summary": "Gain Therapeutics Inc. (NASDAQ:GANX) saw its shares rise significantly after the FDA cleared its Investigational New Drug application for GT-02287, a Parkinson\u2019s disease treatment. This clearance allows the company to initiate a Phase 2 clinical trial in the U.S. in Q3 2026, foll", "url": "https://m.in.investing.com/news/stock-market-news/gain-therapeutics-stock-surges-on-fda-clearance-for-parkinsons-drug-93CH-5475234?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-06-29T20:41:44", "published_display": "29 Jun 2026 20:41", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) wins FDA IND clearance to start GT-02287 Phase 2 Parkinson\u2019s trial", "summary": "Gain Therapeutics (GANX) announced that the FDA has authorized its Investigational New Drug (IND) application for GT-02287. This clearance allows the company to proceed with Phase 2 clinical trials in the United States for Parkinson's disease, with or without a GBA1 mutation. The", "url": "https://www.stocktitan.net/sec-filings/GANX/8-k-gain-therapeutics-inc-reports-material-event-efa118a2710f.html", "source_name": "Stock Titan", "published_at": "2026-06-29T20:41:44", "published_display": "29 Jun 2026 20:41", "sentiment": "positive", "sentiment_pct": 68, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA clears Gain Therapeutics drug GT-02287 for Phase 2 Parkinson\u2019s trial", "summary": "Gain Therapeutics (NASDAQ: GANX) has received FDA clearance for its Investigational New Drug (IND) application for GT-02287, allowing it to proceed with Phase 2 clinical development for Parkinson's disease in the U.S. This decision follows positive Phase 1 results that showed fav", "url": "https://www.stocktitan.net/news/GANX/gain-therapeutics-receives-fda-clearance-of-ind-to-advance-gt-02287-lw5rfm3izgpz.html", "source_name": "Stock Titan", "published_at": "2026-06-29T19:41:44", "published_display": "29 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 93, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Gain Therapeutics, Inc. \u2013 NASDAQ:GANX", "summary": "This article provides information about the \"Price to earnings forward\" for Gain Therapeutics, Inc. (NASDAQ: GANX). It appears to be a financial data point available on TradingView, indicating a specific financial metric for the company. The content itself seems to be a financial", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T15:41:44", "published_display": "29 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Clinical-Stage Biotech Stocks Worth Watching In Parkinson's Research", "summary": "This article highlights three clinical-stage biotech companies, Gain Therapeutics (GANX), MeiraGTx Holdings (MGTX), and Alto Neuroscience (ANRO), that are actively involved in Parkinson's research. It discusses their current clinical progress, market capitalization, revenue, and ", "url": "https://www.sahmcapital.com/news/content/3-clinical-stage-biotech-stocks-worth-watching-in-parkinsons-research-2026-06-26", "source_name": "Sahm", "published_at": "2026-06-25T23:41:44", "published_display": "25 Jun 2026 23:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics, Inc. Actuals & Estimates (NASDAQ:GANX)", "summary": "This article provides an overview of Gain Therapeutics, Inc. (NASDAQ:GANX) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, such as earnings per share and revenue, and addresses common investor question", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T22:10:26", "published_display": "25 Jun 2026 22:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) shareholders back board slate and Ernst & Young AG at 2026 meeting", "summary": "Gain Therapeutics, Inc. held its annual stockholder meeting on June 24, 2026, where shareholders elected seven directors to one-year terms and ratified Ernst & Young AG as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The director", "url": "https://www.stocktitan.net/sec-filings/GANX/8-k-gain-therapeutics-inc-reports-material-event-325237341616.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:59:39", "published_display": "25 Jun 2026 20:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GANX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Gain Therapeutics, Inc. (GANX) stock, including analyst price targets, historical performance, and essential financial data. It highlights that five analysts have offered a 1-year price forecast, with a maximum estimate of $8.00 and a minimum ", "url": "https://www.tradingview.com/symbols/NASDAQ-GANX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T17:09:57", "published_display": "25 Jun 2026 17:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Inc (GANX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Gain Therapeutics Inc (GANX), detailing its price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock currently has a price momentum score of 7.01 and is trading betwee", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ganx/technical", "source_name": "TradingKey", "published_at": "2026-06-22T09:10:59", "published_display": "22 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Inc (GANX) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Gain Therapeutics Inc (GANX), highlighting its current earnings forecast score of 8.80 within the Biotechnology & Medical Research industry. It details analyst ratings, with a strong buy consensus and a target price of $7.00, along w", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ganx/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T20:09:56", "published_display": "19 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Inc (GANX) Institutional Confidence", "summary": "Gain Therapeutics Inc (GANX) has an institutional shareholding score of 3.00, ranking 193rd out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 20.25%, marking a 58.16% increase quarter-over-quarter. Bill Nygren | OAKMX", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ganx/sentiment", "source_name": "TradingKey", "published_at": "2026-06-19T03:10:58", "published_display": "19 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Inc (GANX) Valuation: PE, PB & Fair Value Analysis", "summary": "Gain Therapeutics Inc (GANX) has a current valuation score of 6.04, placing it in the lower quartile of the Biotechnology & Medical Research industry. The company's P/E ratio stands at -3.21, significantly below its recent high but above its recent low. Key valuation metrics like", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-ganx/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T03:10:58", "published_display": "19 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gain-therapeutics-present-h-c-110000181.html", "source_name": "GlobeNewswire", "published_at": "2026-06-10T11:00:00+00:00", "published_display": "10 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics expands \u2018compelling\u2019 evidence base for Parkinson\u2019s candidate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gain-therapeutics-presents-positive-interim-120000888.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T12:00:00+00:00", "published_display": "26 May 2026 12:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/gain-therapeutics-reports-financial-results-110000886.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T11:00:00+00:00", "published_display": "11 May 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNMFFpOWNoOEhDSXBMaWpoLXBmQkVkS1pZZ0JRSF9Ibk8xRGNpeVlzc2h3MkRiVnhwa3pPOXg3d2UwNE9FbVpGblZRVnAxMkttN3FmWVU4VnpROXlWSEpKeWw5aVVqQ3lyNmtpaUtwZDNROGdwWDY3WFNDOWFmQVQ5emF2VUZ4aFlaYngzVE4tdmhkNUY1Y2VIQVhTUnpDMjZGakwyMVh3?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GANX | Gain Therapeutics, Inc. Common Insider Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTFBWS3RXREJELUd6YXJaYXNPbzVJQWR0UWhJSXJXUTNUUUxkT1Z1cUMyYTZnWVZ0YWtWUTgzbGw0NEtjMnpfTlZJNDJNa1k5NFJFQXNKbGdrZW8zb0hB?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-17T06:43:50+00:00", "published_display": "17 Apr 2026 06:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech firm Gain Therapeutics lines up three events in San Francisco", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNaXR1ZW04TVZoc3JOdkNHdEVwOUswaGx3Ti1vZXpZTHI3Sk1aX0RQTjdGWjRrY2EzalVsZU1taTkzQjRud3RIRnhWZ09taWNQbnNlc2NJbUEwM21ocDlTUEVXVEpQZkZWeG9jREJ0VDJWYUxYR0RNRy1BTmlJZ0MxTldYcm9JTnFWaWQ3ZXkyb0NqVGhmSzg1NzF0RjhPNlgyZnRSbkhkTjBtTEhDakdpZk5tdENKaXJn?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) Upgraded to Buy: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdFlUSGl6TXE1eGNVUThXNTFITFlxb0hFRnprc3Rmam83TGVpRTZyTUJMNmVBODJzb3BrRjd1S3BORG05VjJuVzlJSnlmZEdNclFVeGVJZHRYenZTLVpncDBKNENSUXVWNDNKLXdQLXc1cm1Cc2ZUTkJXOVp1enlpTlQ4QWNEUjlV?oc=5", "source_name": "Market source", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics Sees Stock Surge Amid Positive Clinical Results and Ambitious Price Target Increase", "summary": "", "url": "https://news.google.com/rss/articles/CBMifEFVX3lxTE9UX2p6YmtINklMOGV4ejIzU2txemZldWdaSElJRkR2anQ3WGctaXdlZkJkbnpOZTlGWTlYVXVuWkpTZERqUU5GTDJxMGNmajhVU2UtaDV0bUN2ejg0UFN6LWcxaVBVZ0lFWHFTRWc3M2VBQUk1WkM3dUdmdkI?oc=5", "source_name": "StocksToTrade", "published_at": "2025-12-21T08:00:00+00:00", "published_display": "21 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxOMF9nc1llWDZqQ1U0T0N4ZEU4TnozWGp1MnJMMnhFTWhyd2FJd0tjQlBTaXFrSWE5YU5DQkx2bFM1VllZRzZQbXowWFdtMkZtZGpvR2pMcjFOT1g3WnRScFhRRVNQZzQxb3QyaUZGcWhZbnNmeGkyVjRvMlJiemdjQjFlRQ?oc=5", "source_name": "Market source", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxQR1ptbTZqU0NuMTR6WnhGaV9mWWFlMWFhLU5uZ3FyQlJ4ci0xRzRTT1V1ZzI2VHFjQTBzWHhwME10cVJKb1VZSjhfMFBxcFdkQWNYNDYyYWVJWFFYaWRaYlg2MUJJZHdwVXhnRGtLSXNackNZWGRvVGdzYzh3X3ZGZ2pPSmNmLWQ0d0tVN21VUEwzemRxbUVnMm1BNmhNc3Vldm5xdGRRWEZ0akFuWHA4Y2xlOXQ4WC01d1o0UXd6cmRmbEU1LWJ2OVVhRlktRnBSQ3RMaXFYUzRrUkg3X3Vsek9B?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-11-07T08:00:00+00:00", "published_display": "07 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFAyLThUNzFudmk1aEFobks0Q1R6WTJpWE5UZ3J4N1hCVjNwVUMyTUx5dlA0WVgxZTR3ZVZmd01ucVhSWTlqRG1hQW5NMXFCa2otekJF?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:56:17+00:00", "published_display": "25 Apr 2025 01:56", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Gain Therapeutics (GANX) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTFBkRWN6VVNUX2xjQjVweGZQUnotLU9UbE1YRHIyb01xV3ZvRGctUmpPeFlpNHZkQy1rVVEydHhTbG83bURocnA3TjJSR1BqQQ?oc=5", "source_name": "Stock Titan", "published_at": "2021-03-21T19:32:46+00:00", "published_display": "21 Mar 2021 19:32", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 51, "sentiment_summary": {"positive": 32, "negative": 4, "neutral": 15, "score": 64, "total": 51, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 11.35, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 8.8, "count": 18}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.85, "count": 7}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}], "positive_events": 32, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 1.8, "latest_week": "2026-07-10", "one_week_move": -5.8, "four_week_move": 7.1, "twelve_week_move": -15.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.068575, "market_dynamics_buy_signal": false, "relative_strength": -26.978724, "fair_value_gap": -24.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.7257, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.8% over one week, +7.1% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Positive news being faded", "tone": "negative", "classification": "positive_rejected", "summary": "Constructive headlines are not being rewarded by price, which raises a rejection flag.", "confidence": 73, "badges": ["Sentiment-trend disagreement", "Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": ["Positive news is arriving while the Sharemaestro trend signal is inactive."], "event_label": "Market update", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 6}, {"label": "Moomoo", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "Quartr", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "simplywall.st", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 18}, {"label": "Regulatory and legal", "count": 7}, {"label": "Analyst action", "count": 6}]}, "insights": [{"label": "Weighted tone", "value": "64/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "Positive news being faded", "tone": "negative", "text": "Constructive headlines are not being rewarded by price, which raises a rejection flag."}, {"label": "Primary event", "value": "Market update", "tone": "positive", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-5.8% over one week, +7.1% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Gain Therapeutics (GANX) Q1 2026 earnings summary"}], "updated_at": "2026-07-16T08:05:37.712907+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}